Goldkorn, A., Ely, B., Quinn, D. I., Tangen, C. M., Fink, L. M., Xu, T., . . . Vogelzang, N. J. (2014). Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer. American Society of Clinical Oncology.
Citação norma ChicagoGoldkorn, Amir, et al. Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer. American Society of Clinical Oncology, 2014.
Citação norma MLAGoldkorn, Amir, et al. Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer. American Society of Clinical Oncology, 2014.